MedTrace Logo

Effects of Energy Drink on Repeated Sprint Performance and Cognitive Function in Athletes

NCT07104188 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-08-05

No results posted yet for this study

Summary

Energy drinks are often used by athletes before competitions to enhance their performance. Recent research has pointed out that the performance effects of select ingredients have been studied individually but not in combination with caffeine. Therefore, this study is designed to investigate the effects of caffeine, anserine, and elderberry on cognitive function and repeated sprint performance of athletes during a high-intensity exercise protocol.

A double-blind, randomized crossover design will be employed. Three types of supplements will be tested: placebo, caffeine (220 mg), and an energy drink containing 220 mg caffeine, 288 mg anserine, 400 mg elderberry, and 660 mg of a vitamin-mineral mixture. Twelve college athletes will be recruited to complete repeated sprint tests on a cycle ergometer until exhaustion and to undertake a series of cognitive tasks during exercise.

Conditions

  • Exercise Performance Impairment
  • Cognitive Function Decline
  • Fatigue

Interventions

DIETARY_SUPPLEMENT

A non-active placebo supplement.

Placebo powder mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.

DIETARY_SUPPLEMENT

Caffeine

220 mg caffeine powder mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.

DIETARY_SUPPLEMENT

Energy Drink

A supplement containing 220 mg caffeine, 1800 mg anserine extract, and 400 mg elderberry extract, mixed into 100 ml grape juice and 200 ml water, consumed 30 minutes before testing.

Sponsors & Collaborators

  • Chien-Wen Hou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-04
Primary Completion
2022-05-10
Completion
2022-06-16

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07104188 on ClinicalTrials.gov